Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02814708Phase 2Completed

Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults

Role: lead

NCT02971670Phase 1Completed

Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial

Role: lead

NCT02340338Phase 1Completed

rTSST-1 Variant Vaccine Phase 1 First-in-man Trail

Role: lead

All 3 trials loaded